Findings from University of Naples Federico II Provides New Data on Multiple Sclerosis (Effect of Siponimod On Lymphocyte Subsets In Active Secondary Progressive Multiple Sclerosis and Clinical Implications).

A recent report from the University of Naples Federico II in Italy explores the role of specific lymphocyte subpopulations in multiple sclerosis (MS), particularly in progressive stages. The study investigated the changes in lymphocytes during siponimod treatment in patients with active secondary progressive MS (aSPMS) and their associations with clinical outcomes. The findings revealed that patients treated with siponimod experienced a reduction in T and B lymphocytes, including CD4+, CD3+CD20+, naive regulatory T cells, and memory regulatory B cells. The study also found that disability progression while on siponimod treatment was associated with a less pronounced effect on B and CD3+CD20+ lymphocytes. [Extracted from the article]